FDA issues CRL to Orexo’s NDA for opioid overdose medication
The US FDA has issued a complete response letter (CRL) to Orexo regarding its NDA for OX124 to counteract opioid overdoses.
The US FDA has issued a complete response letter (CRL) to Orexo regarding its NDA for OX124 to counteract opioid overdoses.
What's Your Reaction?
